Briumvi (ublituximab-xiij)

Covered for adults (≥18) with relapsing forms of MS (clinically isolated, relapsing‑remitting, active secondary progressive) and not covered for pediatric patients or non‑relapsing forms (e.g., primary progressive) or other off‑label uses. Key requirements: prescribed by or in consultation with an MS specialist, prior inadequate efficacy or intolerance to ≥1 MS disease‑modifying therapy, follow the specified IV dosing (150 mg, 450 mg at 2 weeks, then 450 mg every 24 weeks), authorizations limited to 12 months, and reauthorization requires objective evidence of benefit or symptom stabilization/improvement after 1 year.

"Treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease."

Sign up to see full coverage criteria, indications, and limitations.